Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report

Blood

Volumn 95, Issue 2, 2000, Pages 416-421

  Reiter, Alfred ^a,f   Schrappe, Martin ^b   Ludwig, Wolf Dieter ^c   Tlemann, Markus ^a   Parwaresch, Reza ^b   Zimmermann, Martin ^d   Schirg, Eckard ^e   Henze, Günter ^e   Schellong, Günther ^b   Gadner, Helmut ^a   Riehm, Hansjörg ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e ST ANNA CHILDREN S HOSPITAL   (Austria)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; MERCAPTOPURINE; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TUMOR REGRESSION;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CRANIAL IRRADIATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, LYMPHOBLASTIC; MALE; METHOTREXATE; NEOPLASM STAGING; PROBABILITY; REMISSION INDUCTION; TIME FACTORS;

EID: 12944293123     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Reiter A, Schrappe M, Parwaresch R, et al. NonHodgkin's lymphomas of childhood and adolescence; results of a treatment stratified for biological subtypes and stage: a report of the BFM Group. J Clin Oncol. 1995;13:359-372.
2. Wollner N, Burchenal JH, Lieberman PH, Exelby P, D'Angio D, Murphy ML Non-Hodgkin's lymphoma in children: a comparative study of two modalities of therapy. Cancer. 1976:37:123-134.
3. Müller-Weihrich S, Henze G, Jobke A, et al. BFMStudie 1975/81 zur Behandlung der NonHodgkin-Lymphome hoher Malignität bei Kindern und Jugendlichen. Klin Pädiatr. 1982:194:219225.
4. 2). N Engl J Med. 1983:308:559-565.
5. 2 therapy in 107 children with nonHodgkin's lymphoma (Burkitt's lymphoma excluded). Cancer. 1985:55:323-336.
6. Dahl GV, Rivera G, Pui CH, et al. A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985;66:1110-1114.
7. Patts C, Kalifa C, Ramant F, et al. Results of the LMT81 protocol: a modified LSA2-L2 protocol with high dose methotrexate, on 84 children with non-B-Cell (lymphoblastic) lymphoma. Med PediatrOncol. 1992;20:105-113.
8. Eden OB, Hann I, Imeson J, Cotterill S, Gerrard M, Pinkerton CR. Treatment of advanced stage T cell lymphoblastic lymphoma: results of the United Kingdom Children's Cancer Study Group (UKCCSG) protocol 8503. Br J Haematol. 1992; 83:310-316.
9. Tubergen DG, Krailo MD, Meadows AT, et al. Comparison of treatment regimens for pédiatrie lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group Study. J Clin Oncol. 1995; 13:1368-1376.
10. Mott MG, Chessells JM, Willoughby MLN, et al. Adjuvant low dose radiation in childhood T cell leukaemia/lymphoma. Br J Cancer. 1984;50:457-462.
11. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993; 11:1208-1215.
12. Ingram L, Mott MG, Mann JR, Raafat F, Darbyshire PJ, Morris Jones PH. Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSO regimens. Br J Cancer. 1987;55:463-466.
13. Bhatia ST Robison LL, Oberiin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996; 334:745-751.
14. Riehm H, Gadner H, Henze G, Langermann HJ, Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol. 1980)2:299-306.
15. Henze G, Langermann HJ, Kaufmann U, et al. Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia. Am J Pediat Hematol Oncol. 1931;3:369-376.
16. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) cooperative group. Br J Haematol. 1976:33:451-458.
17. Ludwig WD, Bartram CR, Ritter J, et al. Ambiguous phenotypes and genotypes in 16 children as characterized by multiparameter analysis. Blood. 1988:71:1518-1528.
18. Stansfeld AG, Diebold J, Kapanci Y, et al. Updated Kiel classification for lymphomas. Lancet 1988;1(8580):292-299.
19. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361 -1392.
20. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
21. Murphy SB. Classification, staging and end results of treatment in childhood non-Hodgkin's lymphoma: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332-339.
22. Weite K, Reiter A, Mempel K, et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood. 1996;87: 3143-3150.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
25. Akritas MG. Bootstrapping the Kaplan-Meier estimator. J Am StatAssoc. 1986;1032-1038.
26. Hvizdala EV, Berard C, Cailihan T, et al. Lymphoblastio lymphoma in children-A randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pédiatrie Oncology Group study. J Clin Oncol. 1988;6:26-33.
27. Weinstein HJ, Cassady JR, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1933:1:537-541.
28. Katz JA, Hvizdala E, Shuster J, Falletta JM, Schwenn M. Murphy SB. Ten year's experience with LSA2-L2 therapy for childhood advanced lymphoblastic lymphoma. J Clin Oncol. 1993;11: 2054-2055.
29. Bergeron CJ, Patte C, Leverger G, et al, and the SFOP France. Treatment of childhood lymphoblastic lymphomas: results of the SFOP LMT 89 Protocol (Société Française d'Oncologie Pédiatrique) [abstract]. Med Pediatr Oncol. 1997;29: 356.
30. Amylon MD, Shuster J, Puiien J, et al. Intensive high-dose asparaginase consolidation improves survival for pédiatrie lymphoma: a Pédiatrie Oncology Group study. Leukemia. 1999;13:335-342.
31. Shepherd SF, A'Hem RP, Pinkerton CR. Childhood T-cell lymphoblastic lymphoma-does early resolution of mediastinal mass predict for final outcome? Br J Cancer. 1995;72:752-756.
32. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84: 3122-3133.
33. Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia: theAssociazone Italiana Ematologia Oncologia Pediatrica (AIEOP). Cancer. 1995:75:1684-1693.
34. van Dongen JJM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia. A prospective study of the International BFM Study Group. Lancet. 1998:352:1731-1738.